Modality
Bispecific Ab
MOA
FXIai
Target
DLL3
Pathway
Epigenetic
SCLC
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
~Apr 2020
→ ~Jul 2021
Phase 2
Oct 2021
→ Jan 2029
Phase 2Current
NCT06774014
31 pts·SCLC
2024-06→2028-10·Not yet recruiting
NCT05644958
682 pts·SCLC
2021-10→2029-01·Not yet recruiting
713 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-01-013mo agoAdCom· SCLC
2028-10-122.5y awayPh3 Readout· SCLC
2029-01-112.8y awayPh3 Readout· SCLC
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029
P2/3
Not yet…
P2/3
Not yet…
Catalysts
AdCom
2026-01-01 · 3mo ago
SCLC
Ph3 Readout
2028-10-12 · 2.5y away
SCLC
Ph3 Readout
2029-01-11 · 2.8y away
SCLC
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06774014 | Phase 2/3 | SCLC | Not yet recr... | 31 | ACR20 |
| NCT05644958 | Phase 2/3 | SCLC | Not yet recr... | 682 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| TAK-8730 | Takeda | Phase 2 | VEGF |